AI brief of an SEC Form 8-K · TRex Bio, Inc. (TRXB)

TRexBio reports Q3 2026 net loss of $13.2 million; October IPO raised $133.5 million

Negative Impact 3 of 5 earnings

TRexBio, a clinical-stage biotechnology company, reported third quarter 2026 results with a net loss of $13.2 million, up from $7.9 million a year earlier, as research and development and administrative costs rose. The company completed a $133.5 million initial public offering in October 2026, and it expects its cash and IPO proceeds to fund operations into the second half of 2029.

Key points

  • Net loss was $13.2 million for Q3 2026, compared with $7.9 million for Q3 2025.
  • R&D expenses were $11.4 million, up from $7.0 million, mainly due to higher clinical trial costs for TRB-061.
  • Cash, cash equivalents and marketable securities were $78.2 million at September 30, 2026, excluding about $119.0 million in IPO net proceeds.
  • Topline Phase 1b data for TRB-061 in atopic dermatitis are expected in mid-2027.

The filing

CompanyTRex Bio, Inc. (TRXB)
Form8-K, current report
Filed with the SECNov 13, 2026, 4:04 PM ET
Accession number0001193125-26-460588

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 13, 2026, 4:11 PM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.